‘Ozempic Face’ Seen Driving Botox Sales, AbbVie Says (Correct)

AbbVie Inc. sees “Ozempic face” — the saggy, hollowed out look some patients report after taking weight-loss drugs — as a potential boon for Botox sales.

“The majority of people who engage in these medical weight-loss products are more interested in aesthetics afterwards,” Carrie Strom, the president of the AbbVie division that sells Botox, said on an earnings call Friday. “We do see it as a long-term tailwind.”

Read More: AbbVie Sees Signs of Post-Humira Growth in Positive 2024 Outlook

People are flocking to weight-loss drugs such as Novo Nordisk A/S’s Wegovy and Eli Lilly & Co.’s ...